Aim: To show the results of intravitreal application of triamcinolone used as a primary or adjuvant therapy.
Patients And Methods: We analyzed 48 patients with different ocular disorders: exudative age related macular degeneration, diabetic retinopathy, or central retinal vein occlusion. We analyzed color fundus photography, visual acuity, fluorescein angiography and complications of intravitreal triamcinolone application.
Results: There was a marked reduction of macular edema in 70% of patients verified on fluorescein angiography. Visual acuity improved in 62% of patients. The most common complication was transient rise in intraocular pressure. There was no case of endophthalmitis.
Conclusion: Intravitreal application of triamcinolone is relatively safe and efficacious in selected patiens with different ocular disorders.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Intravitreal melatonin for the prevention of radiation retinopathy: a step beyond bevacizumab.
Int J Radiat Biol
January 2025
Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Purpose: Intravitreal bevacizumab has been utilized to mitigate radiation retinopathy, yet the potential role of intravitreal melatonin for its prevention remains unexplored. This study aims to evaluate and compare the efficacy of intravitreal melatonin and bevacizumab in preventing radiation retinopathy in an experimental animal model.
Materials And Methods: Twelve healthy male New Zealand white rabbits ( = 24 eyes) received a single 3000 cGy irradiation dose in both eyes.
A membrane-targeted photoswitch restores physiological ON/OFF responses to light in the degenerate retina.
Nat Commun
January 2025
Center for Synaptic Neuroscience, Istituto Italiano di Tecnologia, Genova, Italy.
The lack of effective therapies for visual restoration in Retinitis pigmentosa and macular degeneration has led to the development of new strategies, such as optogenetics and retinal prostheses. However, visual restoration is poor due to the massive light-evoked activation of retinal neurons, regardless of the segregation of visual information in ON and OFF channels, which is essential for contrast sensitivity and spatial resolution. Here, we show that Ziapin2, a membrane photoswitch that modulates neuronal capacitance and excitability in a light-dependent manner, is capable of reinstating, in mouse and rat genetic models of photoreceptor degeneration, brisk and sluggish ON, OFF, and ON-OFF responses in retinal ganglion cells evoked by full-field stimuli, with reactivation of their excitatory and inhibitory conductances.
View Article and Find Full Text PDFApplications and latest research progress of liposomes in the treatment of ocular diseases.
Biointerphases
January 2025
Department of Pharmaceutical Sciences, State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Dalian, Liaoning 116081, China.
The special structure of eyes and the existence of various physiological barriers make ocular drug delivery one of the most difficult problems in the pharmaceutical field. Considering the problems of patient compliance, local administration remains the preferred method of drug administration in the anterior part of eyes. However, local administration suffers from poor bioavailability, need for frequent administration, and systemic toxicity.
View Article and Find Full Text PDFSafety and efficacy of supraciliary dexamethasone implantation for macular oedema: a preliminary comparative study.
Eye (Lond)
January 2025
Department of Ophthalmology, Bursa Uludag University School of Medicine, Bursa, Turkey.
Purpose: To evaluate the efficacy and safety of dexamethasone implantation in the supraciliary (SC) space, a novel and potential effective implantation site, compared to intravitreal (IV) application.
Methods: This prospective study included 39 eyes of 38 patients with macular oedema (ME) who underwent SC and IV dexamethasone implantation (SC-DEX and IV-DEX). Patients were randomly assigned to treatment groups and followed for 3 months.
Potential Use of Plasma Rich in Growth Factors in Age-Related Macular Degeneration: Evidence from a Mouse Model.
Medicina (Kaunas)
December 2024
BTI Biotechnology Institute, 01005 Vitoria, Spain.
: Age-related macular degeneration (AMD) is the leading cause of low vision and legal blindness in adults in developed countries. Wet AMD can be successfully treated using vascular endothelial growth factor (VEGF) inhibitors; however, dry AMD currently has no effective treatment. The purpose of this study is to analyze the efficacy of intraocular injection of plasma rich in growth factors (PRGF) in an AMD mouse model induced by intraperitoneal administration of sodium iodate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!